Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Puma Biotechnology Sees Q2 Net Product Revenue $43M-$45M; FY24 Net Product Revenue $183M-$190M

Author: Benzinga Newsdesk | May 02, 2024 05:59pm

Second Quarter and Full Year 2024 Financial Outlook

 Second Quarter 2024Full Year 2024
Net Product Revenue$43 -45 million$183 - $190 million
Royalty Revenue$2.5 - $3 million$30 - $33 million
License Revenue$0 million$1 - $2 million
Net Income/(Loss)$(6) - $(9) million$12 - $15 million
Gross to Net Adjustment22% - 23%21.5% - 22.5%


 

Posted In: PBYI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist